Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.50 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.50 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.50 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.50 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.94 |
| ▸ | TSHR | P16473 | 3/20 | 0.94 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.70 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.52 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL236597 | 0.97 | ALDH1A1 (0.90) | ALDH1A1TSHRTAAR1AOC3HRH3 | |
| Hydrochloric Acid SCHEMBL782950 | 0.97 | ALDH1A1 (0.90) | ALDH1A1TSHRTAAR1AOC3HRH3 | |
| SCHEMBL27766437 | 0.97 | TSHR (1.00) | ALDH1A1TSHRTAAR1AOC3HRH3 | |
| SCHEMBL15900 | 0.97 | TSHR (1.00) | ALDH1A1TSHRTAAR1AOC3HRH3 | |
| SCHEMBL5014268 | 0.97 | TSHR (1.00) | ALDH1A1TSHRTAAR1AOC3HRH3 | |
| SCHEMBL24735547 | 0.97 | TSHR (1.00) | ALDH1A1TSHRTAAR1AOC3HRH3 | |
| Bromide SCHEMBL414532 | 0.94 | TSHR (0.94) | ALDH1A1TSHRTAAR1AOC3HRH3 | |
| Iodide SCHEMBL6672021 | 0.94 | TSHR (0.94) | ALDH1A1TSHRTAAR1AOC3HRH3 | |
| SCHEMBL7911439 | 0.94 | TSHR (0.94) | ALDH1A1TSHRTAAR1AOC3HRH3 | |
| Hydrochloric Acid SCHEMBL6391891 | 0.94 | TSHR (0.94) | ALDH1A1TSHRTAAR1AOC3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108262030-A | Preparation method and application of titanium-containing silicon oxide material with high thermal stability | 东联化学股份有限公司 | 2018-07-10 | — | — | CN | claimed |
| CN-104876826-B | A kind of synthetic method of the double benzyl chlorides of renewable accelerant and application | 西南大学 | 2017-06-13 | — | — | CN | claimed |
| CN-104876826-A | Synthesis method and application of reproducible dyeing accelerant bisbenzyl dimethyl ammonia chloride | UNIV SOUTHWEST | 2015-09-02 | — | — | CN | claimed |
| CN-101365449-B | Nanoparticulate benzothiophene formulations | ELAN PHARMA INT LTD | 2011-11-09 | — | — | CN | claimed |
| CN-101797245-A | Nanoparticulate fibrate formulations | ELAN PHARMA INT LTD | 2010-08-11 | — | — | CN | claimed |
| CN-101797233-A | Nanoparticulate fibrate formulations | ELAN PHARMA INT LTD | 2010-08-11 | — | — | CN | claimed |
| CN-101365449-A | Nanoparticulate benzothiophene formulations | ELAN PHARMA INT LTD (IE) | 2009-02-11 | — | — | CN | claimed |
| CN-101262860-A | Nanoparticulate acetaminophen formulations | ELAN PHARMA INT LTD (IE) | 2008-09-10 | — | — | CN | claimed |
| CN-101242810-A | Nanoparticulate megestrol formulations | ELAN PHARMA INT LTD (IE) | 2008-08-13 | — | — | CN | claimed |
| CN-101232870-A | Nanoparticulate imatinib mesylate formulations | ELAN PHARMA INT LTD (IE) | 2008-07-30 | — | — | CN | claimed |
| CN-101132768-A | Nanoparticulate tacrolimus formulations | ELAN PHARMA INT LTD (IE) | 2008-02-27 | — | — | CN | claimed |
| CN-101106972-A | Injectable nanoparticulate olanzapine formulation | ELAN PHARMA INT LTD (IE) | 2008-01-16 | — | — | CN | claimed |
| CN-1668281-A | Nanoparticulate fibrate formulations | ELAN PHARMA INT LTD (IE) | 2005-09-14 | — | — | CN | claimed |
| EP-0493417-B1 | PROCESS FOR DETERMINING VERY SMALL QUANTITIES OF HERBICIDES BASED ON TRIAZINE COMPOUNDS | HOELZLE & CHELIUS GMBH (DE) | 1994-03-02 | — | — | EP | claimed |
| US-4117013-A | AMINES, QUATERNARY AMMONIUM COMPOUNDS, OLEFIN EPOXIDES, HYDROXYQUI(OLINES, AMINE PHENOXIDES, GLYCIDYL HALIDES AND ETHERS | UNITED TECHNOLOGIES CORPORATION (US) | 1978-09-26 | — | — | US | claimed |
| US-12630650-B2 | Engineered IgA antibodies and methods of use | TIGATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12473370-B2 | TL1A associated antibody compositions and methods of use | Absci Corporation (US) | 2025-11-18 | — | — | US | disclosed |
| WO-1991004481-A1 | PROCESS FOR DETERMINING VERY SMALL QUANTITIES OF HERBICIDES BASED ON TRIAZINE COMPOUNDS | HOELZLE & CHELIUS GMBH (DE) | 1991-04-04 | — | — | WO | disclosed |
| US-4622335-A | AGRICULTURE | BAYER AKTIENGESELLSCHAFT (DE) | 1986-11-11 | — | — | US | disclosed |
| US-4459185-A | SURFACTANT, LEVELING AGENTS | OBATA, DONI, DAIWA, FINE CHEMICALS CO., LTD. (JP) | 1984-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630650-B2 | Engineered IgA antibodies and methods of use | IGLV6-57, IGSF11, FCGR2A | ADRA2B 3183/4885ADRA2C 2409/4885SLC6A2 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.